Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

NCT03842085 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2-positive Recurrent or Metastatic Malignant Solid Tumor

Interventions

DRUG: Recombinant Humanized Bispecific Monoclonal Antibody MBS301

Sponsor

Beijing Mabworks Biotech Co., Ltd.